Natural 'brake' against malignant neuroblastoma turns tumors benign

Natural "brake" against malignant neuroblastoma
Tamara Weiss, PhD, and Sabine Taschner-Mandl, PhD, discover that the uncontrolled growth of neuroblastomas (green tumor cells) is stopped by a signal molecule produced by Schwann cells (magenta). Credit: Photo: Sabine Taschner-Mandl, PhD, and Tamara Weiss, PhDCopyright: St. Anna Children's Cancer Research InstituteImage: Immunofluorescence image of Schwann cells (magenta) and neuroblastoma cells (green) Copyright: Weiss T, Taschner-Mandl S et al., Nature Communications 2021

A factor that turns malignant tumors into benign ones? That is exactly what scientists at St. Anna Children's Cancer Research Institute have discovered. Together with colleagues from the Medical University of Vienna and the University of Vienna (Faculty of Chemistry), they studied tumors of the peripheral nervous system in children, namely neuroblastomas. The scientists discovered that the uncontrolled growth of benign neuroblastomas is stopped by a signal molecule produced by Schwann cells present within these tumors. This natural "brake" also works on malignant neuroblastoma cultures. The study, published in the journal Nature Communications, describes for the first time the function of this signal molecule—not only in tumors, but also in injured nerve fibers.

What sounds contradictory at first glance, namely firing a tumor with a growth factor, makes sense in . Neuroblastoma is a tumor of the peripheral nervous system and the most common solid cancer in early childhood. In contrast to malignant neuroblastomas, benign neuroblastomas contain many Schwann cells. These cells normally protect and repair cells. The results of the new study indicate that Schwann cells in neuroblastoma stimulate tumor cells to mature, thereby halting their unchecked growth.

A cell that stops tumor growth

To accomplish this, Schwann cells produce, among other factors, a signaling molecule called epidermal growth factor like 8 (EGFL8). The research team demonstrates that EGFL8 stimulates the differentiation, or maturation, of neuroblastoma cells. "Until recently, we only knew that this protein existed, but its function was not known. We now for the first time know where EGFL8 is produced and how it acts," explains study author Sabine Taschner-Mandl, Ph.D., head of the Tumor Biology Group at St. Anna Children's Cancer Research Institute. Furthermore, the study results show that high levels of EGFL8 was associated with better survival rates in neuroblastoma patients.

"In cell cultures, we have demonstrated that Schwann cells as well as their secreted signaling molecules exert anti-tumor effects, even in aggressive neuroblastoma cells. Thus, we are able to exploit a process that occurs naturally in benign neuroblastomas to stop the malignant ones," Sabine Taschner-Mandl and her colleague Tamara Weiss, Ph.D., from the Medical University of Vienna, explain. In addition to EGFL8, other, yet uncharacterized Schwann cell molecules could also provide targets for cancer therapies in the future.

However, the effects of Schwann cells are presumably much more extensive: the research team is currently investigating how Schwann cells manipulate immune cells in their environment.

The present study provides another significant finding: Schwann cells in benign neuroblastomas have a similar cellular status to those Schwann cells that support the healing of injured peripheral nerves. Direct comparison revealed that Schwann cells in the tumor express certain repair-associated genes and show specific repair functions. "It is amazing that we have discovered a signaling molecule that plays a role in both development of benign neuroblastomas and regeneration of injured nerves. Since EGFL8 stimulates the formation of nerve cell extensions, it could be of great importance for the treatment of injured nerve fibers", says Tamara Weiss.

Prospective application in aggressive tumors

It is conceivable that EGFL8 and other factors produced by Schwann cells could be applied in the treatment of nerve damage as well as aggressive neuroblastoma. "Using phosphoproteomics, we were able to decipher which signaling pathways are activated by EGFL8 in neuroblastoma cells. There are major differences compared to that have not been stimulated with EGFL8," Sabine Taschner-Mandl says. In addition to EGFL8, these downstream signaling pathways also represent potential targets for future treatments. "There is still a long way to go before these findings ultimately reach the patient. But we have now laid the foundation for taking the next steps."


Explore further

Research finds new Rx target for childhood cancer

More information: Schwann cell plasticity regulates neuroblastic tumor cell differentiation via epidermal growth factor like protein 8, Nature Communications (2021). DOI: 10.1038/s41467-021-21859-0
Journal information: Nature Communications

Provided by St. Anna Children's Cancer Research Institute
Citation: Natural 'brake' against malignant neuroblastoma turns tumors benign (2021, March 12) retrieved 25 January 2022 from https://medicalxpress.com/news/2021-03-natural-malignant-neuroblastoma-tumors-benign.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
128 shares

Feedback to editors